Non-interventional Study to Investigate the Short and Long Term Real-life Safety, Effectiveness, and Adherence of Velphoro® in Patients With Hyperphosphataemia Undergoing Haemodialysis (HD) or Peritoneal Dialysis (PD)

CompletedOBSERVATIONAL
Enrollment

1,400

Participants

Timeline

Start Date

April 6, 2016

Primary Completion Date

April 6, 2019

Study Completion Date

April 6, 2019

Conditions
Hyperphosphatemia
Interventions
DRUG

sucroferric oxyhydroxide

The non-interventional design allows the observation of patients in a broad range of settings reflecting routine clinical practice. All decisions on therapeutic or diagnostic procedures, treatments, management of the disease, or resource utilisation will be at the full discretion of the treating physician without interference by a sponsor or study protocol. All treatment decisions will follow the real-life treatment behaviour.

Trial Locations (7)

69495

Centre Hospitalier LYON-SUD, Pierre-Bénite

96450

Klinikum Coburg, Coburg

Unknown

General Hospital of Athens Laiko, Athens

Ospedale Maggiore Policlinico, Milan

Hospital Universitario Marqués de Valdecilla, Santander

Salford Royal Hospitals NHS Trust, Manchester

1007 MB

VU University Medical Center, Amsterdam

All Listed Sponsors
lead

Vifor Fresenius Medical Care Renal Pharma

INDUSTRY

NCT02687594 - Non-interventional Study to Investigate the Short and Long Term Real-life Safety, Effectiveness, and Adherence of Velphoro® in Patients With Hyperphosphataemia Undergoing Haemodialysis (HD) or Peritoneal Dialysis (PD) | Biotech Hunter | Biotech Hunter